Beasley Allen Disqualified From NJ Talc MDL
NJ appeals court disqualifies Beasley Allen from 3,600 talc cases after former J&J lawyer collaborated with firm on adverse settlement strategy.
The New Jersey Appellate Division has disqualified Beasley Allen, one of the largest plaintiff’s firms in talc litigation, from representing clients in the state’s multicounty litigation against Johnson and Johnson.
The ruling, issued February 7, 2026, affects 3,600 cases in New Jersey state court. It could also open the door for J&J to seek the firm’s removal from thousands of additional cases in federal court.
What Happened
At the center of the case is James Conlan, a former partner at Faegre Drinker Biddle and Reath who defended J&J in talc litigation from July 2020 to March 2022. During that time, Conlan billed 1,600 hours and $2.24 million in fees, gaining access to J&J’s confidential defense strategies, settlement valuations, and claim assessment processes.
After leaving Faegre Drinker in March 2022, Conlan founded Legacy Liability Solutions. Starting in April 2023, he began collaborating with Beasley Allen partner Parker Birchfield on a strategy to oppose J&J’s preferred bankruptcy resolution and pitch an alternative settlement structure.
The plan, called “structural optimization,” involved Legacy purchasing J&J units responsible for talc liabilities and distributing funds to claimants outside of bankruptcy. Conlan proposed a $19 billion settlement to J&J’s board, which the company rejected.
The Ethics Violations
J&J discovered the collaboration and moved to disqualify Beasley Allen. The trial court initially denied the motion, but the Appellate Division reversed that decision.
The appeals court found violations of five Rules of Professional Conduct. RPC 1.9(a) bars representing a client in a matter substantially related to a former client’s case where the interests are materially adverse. RPC 1.9(c) prohibits using confidential information from a former client’s representation without consent. RPC 5.3 requires supervision of nonlawyers whose conduct would violate ethics rules if committed by a lawyer. RPC 8.4(a) forbids assisting another in violating professional conduct rules. RPC 1.10 imputes those conflicts across the firm.
The court rejected Beasley Allen’s argument that Conlan was acting as a nonlawyer businessman, not a lawyer, when he collaborated with Birchfield. The panel called that defense “disingenuous.”
Why This Matters for Talc Litigation
Beasley Allen is a leading firm in talc litigation nationwide, representing tens of thousands of plaintiffs who allege that J&J’s talc products contained asbestos and caused cancer.
The disqualification raises questions about the status of the 3,600 New Jersey cases and how they will proceed. It also raises the possibility that J&J could use this ruling to challenge Beasley Allen’s participation in the federal multidistrict litigation, where a joint evidentiary hearing on the ethics issues had already taken place.
The ruling comes at a pivotal moment. J&J’s attempts to resolve talc claims through bankruptcy have failed twice. Juries across the country have delivered massive verdicts, including $1.5 billion to Cherie Craft in Baltimore and $966 million to Mae Moore’s family in California.
More than 67,000 talc lawsuits remain pending nationwide.
What This Means for Plaintiffs
The ruling does not dismiss any cases or affect the underlying claims against J&J. Many of the 3,600 affected plaintiffs may have co-counsel or other firms already handling their cases. The disqualification applies to Beasley Allen’s role in the New Jersey MCL, not to the claims themselves.
References
NJ Courts. In re Talc Based Powder Products, A-0215-24.
https://www.njcourts.gov/system/files/court-opinions/2026/a0215-24.pdf
Legal Newsline. Beasley Allen DQ'd from talc cases for working with ex-J&J lawyer.
https://www.legalnewsline.com/attorneys-and-judges/beasley-allen-dq-d-from-talc-cases-for-working-with-ex-j-j-lawyer/article_1332f029-5642-4db2-b30a-9b19533def48.html
Claims Journal. J&J Rejected $19 Billion Baby Powder Cancer Accord.
https://www.claimsjournal.com/news/national/2023/12/08/320851.htm
Reader Q&A
Frequently Asked Questions
Why was Beasley Allen disqualified from the NJ talc litigation?
The New Jersey Appellate Division found that Beasley Allen collaborated with a former J&J defense lawyer who had access to the company’s confidential litigation strategies. The court ruled this violated multiple ethics rules and disqualified the firm from 3,600 cases.
Does this affect talc cases outside New Jersey?
The ruling applies directly to New Jersey state court cases only. However, J&J may attempt to use this decision to disqualify Beasley Allen from the federal multidistrict litigation as well.
What happens to plaintiffs whose cases involved Beasley Allen?
The underlying claims remain valid. Many plaintiffs in mass tort litigation have co-counsel arrangements, and the disqualification does not affect the merits of any individual case against J&J.
How many talc lawsuits are pending against J&J?
More than 67,000 talc lawsuits remain pending against Johnson and Johnson as of early 2026, making it one of the largest mass tort litigations in US history.
How much will I get from Johnson and Johnson settlement?
No global Johnson & Johnson talcum powder settlement exists as of May 2026, with the latest $9 billion proposal rejected by a Texas bankruptcy judge in April 2025. Individual talcum powder lawsuit payouts for people with mesothelioma linked to asbestos-contaminated talc have ranged from $1 million to $1.4 million on average, based on legal industry estimates and verdicts like a $45 million award (including $32.6 million compensatory) in Illinois. Factors such as injury severity, medical costs, lost wages, and case details influence amounts, with some verdicts reduced on appeal, such as a California case dropping from $966 million to $16 million in March 2026. Overall talc lawsuit settlements average around $500,000 per plaintiff across ovarian cancer and mesothelioma claims. Settlement terms are often confidential, and companies settle without admitting liability.
Has anyone received a settlement from Johnson & Johnson?
Yes, people with mesothelioma and ovarian cancer have received settlements from Johnson & Johnson for claims involving asbestos-contaminated talc products. Notable examples include a $700 million multistate settlement in 2024 for deceptive marketing practices and a $100 million settlement in 2020 resolving over 1,000 claims. Verdicts with settlements have ranged from $45 million in an Illinois mesothelioma case to $966 million in a California case, though global settlement proposals like J&J’s $9 billion offer were rejected as of 2025. Ongoing lawsuits number around 67,000 in New Jersey.
Is it too late to sue Johnson and Johnson?
No, it is not too late to sue Johnson & Johnson for talcum powder claims as of May 2026. The multidistrict litigation (MDL) includes 67,623 pending claims, with new lawsuits still being added monthly. Statutes of limitations vary by state, typically 1-6 years from cancer diagnosis or a loved one’s death, so people with mesothelioma or ovarian cancer from alleged asbestos in talc products may still qualify depending on their timeline. Three J&J subsidiary bankruptcy attempts to resolve claims have been rejected, keeping cases active. Trial lawyers continue filing suits amid ongoing mediation.
What is the average settlement for asbestos exposure?
Settlement amounts for asbestos exposure vary significantly based on diagnosis. People with mesothelioma typically receive pre-trial settlements ranging from $1 million to $2.4 million, while those with asbestos-related lung cancer average $250,000 to $400,000. Non-malignant asbestos-related conditions like asbestosis generally settle for $10,000 to $50,000, though trust fund payouts for these conditions average $300,000 to $400,000 across all trusts. Trial verdicts are substantially higher, with mesothelioma cases averaging around $9 million when they reach jury verdict. Settlement amounts depend on factors including diagnosis certainty, strength of exposure evidence, number of liable defendants, and case jurisdiction.